Dihydronicotinamide riboside
Based on 1 publication(s) in Google Scholar
Dihydronicotinamide riboside is a potent NAD+ concentration enhancer. Dihydronicotinamide riboside modulates targets BAX, PUMA, NQO2, and IκB kinase. Dihydronicotinamide riboside mediates apoptosis, induces pro-oxidant activity, mitochondrial dysfunction, metabolic dysregulation, redox modulation, and pro-inflammatory M1 phenotype induction. Dihydronicotinamide riboside increases intracellular and mitochondrial NAD+ levels, maintains cell survival against NAD+-depleting genotoxins. Dihydronicotinamide riboside can be used for the research of hepatocellular carcinoma.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 95.0%
- CAS. Nr.: 19132-12-8
- Formel: C11H16N2O5
- Molecular Weight:256.26
-
Speicherung:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Dihydronicotinamide riboside
More
Biologische Aktivität
Beschreibung
In Vitro
Dihydronicotinamide riboside (100-1000 μM; 24 h followed by 48 h in fresh medium) induces dose-dependent cytotoxicity in HepG3 cells but has no cytotoxic effect on HEK293T cells[1].
Dihydronicotinamide riboside (500 μM; 24 h with total incubation periods of 24, 48, 72 h) induces PUMA- and BAX-mediated apoptosis in HepG3 cells, with BAX expression peaking at 72 h and PUMA expression peaking at 72 h, while HEK293T cells show no significant changes in apoptotic marker expression[1].
Dihydronicotinamide riboside (100 μM; 1, 4, 24 h) induces a transient but significant increase in cellular ROS levels in HepG3 cells at 4 h, while HEK293T cells show no change in ROS levels over 1, 4, or 24 h of exposure[1].
Dihydronicotinamide riboside (100 μM; 1, 4, 24 h) increases intracellular NAD(P)H levels in both HEK293T and HepG3 cells, with HEK293T cells showing a progressive increase over 24 h and HepG3 cells showing a peak increase at 4 h followed by a slight decline[1].
Dihydronicotinamide riboside (100 μM; 1, 4, 24 h) alters the glutathione redox balance in HEK293T and HepG3 cells, causing a sustained decrease in GSSG levels in HEK293T cells and a transient decrease in GSSG levels in HepG3 cells at 4 h, with no significant changes in GSH levels in either cell line[1].
Dihydronicotinamide riboside (100 μM; 1, 4, 24 h) induces a significant and sustained increase in mitochondrial superoxide production in HepG3 cells, while HEK293T cells show no change in mitochondrial superoxide levels over the same exposure periods[1].
Dihydronicotinamide riboside (100-2000 μM; 1-18 h) potently increases NAD+ concentrations in multiple immortalized mammalian cell lines, with an EC50 of 310 μM in Neuro2a cells, achieving up to 10-fold elevation over control values after 6 h of treatment[2].
Dihydronicotinamide riboside (1 mM; 6 h) increases NAD+ concentrations in HAP1 cells independently of Nrk1, achieving a 6.8-fold elevation over control values after 6 h of treatment with 1 mM NRH in both wild-type and Nrk1 knockout cells[2].
Dihydronicotinamide riboside (NRH) (500 μM; 6 h) significantly boosts intracellular NAD+ levels in both undifferentiated and Phorbol 12-myristate 13-acetate (PMA) (HY-18739)-differentiated human THP-1 monocytic cells, with a stronger effect observed in undifferentiated cells[3].
Dihydronicotinamide riboside (NRH) (500 μM; 6 h) induces significant pro-inflammatory gene expression in PMA-differentiated human THP-1 macrophage-like cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human embryonic kidney (HEK293T) cells, human hepatocellular carcinoma (HepG3) cells
-
Concentration:100, 250, 500, 750, 1000 μM
-
Incubation Time:24 h, followed by 48 h in fresh medium
-
Result:Induced 15%, 50%, 90% cytotoxicity in HepG3 cells at 100, 250, ≥500 μM, respectively.
Showed no cytotoxicity in HEK293T cells across all tested concentrations.
-
Cell Line:human embryonic kidney (HEK293T) cells, human hepatocellular carcinoma (HepG3) cells
-
Concentration:500 μM
-
Incubation Time:24 h, with total incubation periods of 24, 48, 72 h
-
Result:Increased BAX expression by 40% at 24 h, 50% at 48 h, and 110% at 72 h in HepG3 cells relative to control.
Increased PUMA expression by 140% at 48 h and 150% at 72 h in HepG3 cells relative to control.
Showed no significant changes in BAX or PUMA expression in HEK293T cells at any time point.
-
Cell Line:human embryonic kidney (HEK293T) cells, human hepatocellular carcinoma (HepG3) cells
-
Concentration:100 μM
-
Incubation Time:1, 4, 24 h
-
Result:Induced a significant reduction in mtDNA amplification (indicating damage) by 57±7.7% at 1 h and 40% at 4 h in HepG3 cells, with recovery to near-control levels by 24 h.
Induced a significant 27% reduction in mtDNA amplification in HEK293T cells at 1 h, with no significant changes at 4 or 24 h.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 8 weeks old)[2]
-
Dosage:1000 mg/kg; 250 mg/kg
-
Administration:i.p.; single dose
-
Result:Increased NAD+ concentrations 2.4-fold in blood, 5.4-fold in liver, 3.1-fold in kidney, 2.2-fold in brain, 1.2-fold in skeletal muscle, and 2.7-fold in epididymal adipose tissue at 1000 mg/kg.
Increased NAD+ concentrations 5.4-fold in liver and 1.8-fold in kidney at 250 mg/kg.
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Cell Cytotoxicity Assay
- Mammalian live/dead viability and cytotoxicity staining
- Annexin V plus membrane-impermeant dye apoptosis staining
- ROS/oxidative-stress fluorescent staining
- Mitochondrial membrane-potential and mitochondrial mass staining
- Apoptosis Solutions
- Research Protocol for Inflammation-related Diseases
- Liver Cancer Modeling
- Cell Viability Determination by MTT Colorimetric Assay
Chemical Information
-
CAS. Nr. 19132-12-8
-
Appearance Solid
-
Molecular Weight 256.26
-
Formel C11H16N2O5
-
Color Yellow to brown
-
SMILES
NC(C1=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)C=CC1)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Lösungsmittel & Löslichkeit
In Vitro:
H2O : 100 mg/mL (390.23 mM; Need ultrasonic)
DMSO : 3.85 mg/mL (15.02 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Sonavane M, et al. Dihydronicotinamide riboside promotes cell-specific cytotoxicity by tipping the balance between metabolic regulation and oxidative stress. PLoS One. 2020;15(11):e0242174. Published 2020 Nov 9. [Content Brief]
[2]. Yang Y, et al. Dihydronicotinamide riboside is a potent NAD+ concentration enhancer in vitro and in vivo. J Biol Chem. 2019 Jun 7;294(23):9295-9307. [Content Brief]
[3]. Chini CCS, et al. Dihydronicotinamide Riboside Is a Potent NAD+ Precursor Promoting a Pro-Inflammatory Phenotype in Macrophages. Front Immunol. 2022;13:840246. Published 2022 Feb 25. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 3.9023 mL | 19.5114 mL | 39.0229 mL | 97.5572 mL |
| 5 mM | 0.7805 mL | 3.9023 mL | 7.8046 mL | 19.5114 mL | |
| 10 mM | 0.3902 mL | 1.9511 mL | 3.9023 mL | 9.7557 mL | |
| 15 mM | 0.2602 mL | 1.3008 mL | 2.6015 mL | 6.5038 mL | |
| H2O | 20 mM | 0.1951 mL | 0.9756 mL | 1.9511 mL | 4.8779 mL |
| 25 mM | 0.1561 mL | 0.7805 mL | 1.5609 mL | 3.9023 mL | |
| 30 mM | 0.1301 mL | 0.6504 mL | 1.3008 mL | 3.2519 mL | |
| 40 mM | 0.0976 mL | 0.4878 mL | 0.9756 mL | 2.4389 mL | |
| 50 mM | 0.0780 mL | 0.3902 mL | 0.7805 mL | 1.9511 mL | |
| 60 mM | 0.0650 mL | 0.3252 mL | 0.6504 mL | 1.6260 mL | |
| 80 mM | 0.0488 mL | 0.2439 mL | 0.4878 mL | 1.2195 mL | |
| 100 mM | 0.0390 mL | 0.1951 mL | 0.3902 mL | 0.9756 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Dihydronicotinamide riboside Related Classifications
HY-W614507 Related Classifications
Powered by Bioz